http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 06:30:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html <p>Atrium Therapeutics, Inc. (Nasdaq: RNA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with a Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.</p> <p>The trial, called Corventis, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. It will enroll approximately 37 participants across two parts: Part A will consist of multiple ascending dose cohorts to assess safety and inform dose selection, and Part B will be a single-arm expansion cohort at http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html Tue, 14 Jul 2026 06:30:24 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html <p>Atrium Therapeutics, Inc. (Nasdaq: RNA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with a Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.</p> <p>The trial, called Corventis, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. It will enroll approximately 37 participants across two parts: Part A will consist of multiple ascending dose cohorts to assess safety and inform dose selection, and Part B will be a single-arm expansion cohort at http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html Tue, 14 Jul 2026 06:30:24 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html <p>Atrium Therapeutics, Inc. (Nasdaq: RNA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with a Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.</p> <p>The trial, called Corventis, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. It will enroll approximately 37 participants across two parts: Part A will consist of multiple ascending dose cohorts to assess safety and inform dose selection, and Part B will be a single-arm expansion cohort at http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html Tue, 14 Jul 2026 06:30:24 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html <p>Atrium Therapeutics, Inc. (Nasdaq: RNA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with a Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.</p> <p>The trial, called Corventis, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. It will enroll approximately 37 participants across two parts: Part A will consist of multiple ascending dose cohorts to assess safety and inform dose selection, and Part B will be a single-arm expansion cohort at http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html Tue, 14 Jul 2026 06:30:24 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html <p>Atrium Therapeutics, Inc. (Nasdaq: RNA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with a Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.</p> <p>The trial, called Corventis, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. It will enroll approximately 37 participants across two parts: Part A will consist of multiple ascending dose cohorts to assess safety and inform dose selection, and Part B will be a single-arm expansion cohort at http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html Tue, 14 Jul 2026 06:30:24 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html <p>Atrium Therapeutics, Inc. (Nasdaq: RNA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with a Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.</p> <p>The trial, called Corventis, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. It will enroll approximately 37 participants across two parts: Part A will consist of multiple ascending dose cohorts to assess safety and inform dose selection, and Part B will be a single-arm expansion cohort at http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html Tue, 14 Jul 2026 06:30:24 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html <p>Atrium Therapeutics, Inc. (Nasdaq: RNA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with a Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.</p> <p>The trial, called Corventis, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. It will enroll approximately 37 participants across two parts: Part A will consist of multiple ascending dose cohorts to assess safety and inform dose selection, and Part B will be a single-arm expansion cohort at http://www.streetinsider.com/FDA/FDA+clears+Atrium+Therapeutics+IND+for+rare+heart+disease+drug/26764439.html Tue, 14 Jul 2026 06:30:24 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html <div class="xn-content"> <p class="prntac"><i>-- ATR 1072 is the company's first precision cardiology program to enter the clinic --</i></p><p class="prntac"><i>-- <span value="ACORN:3169166301" idsrc="xmltag.org" >Corventis</span></i>™ <i>will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Announces+FDA+Clearance+of+Investigational+New+Drug+Application+for+ATR+1072+for+Treatment+of+PRKAG2+Syndrome/26764431.html Tue, 14 Jul 2026 06:30:00 -0400 A.06822034 A.31691663 A.50217003 O.08045350 O.20026344 O.76946938 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>June 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of eight non-executive individuals newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html Tue, 23 Jun 2026 16:05:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>June 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of eight non-executive individuals newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html Tue, 23 Jun 2026 16:05:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>June 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of eight non-executive individuals newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html Tue, 23 Jun 2026 16:05:00 -0400 A.50217003 O.76946938 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5021700326" idsrc="xmltag.org" >Atrium Therapeutics, Inc.</span> (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on <chron>June 20, 2026</chron> under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of eight non-executive individuals newly hired by the Company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26679440.html Tue, 23 Jun 2026 16:05:00 -0400 A.50217003 O.76946938 RNA RNA